Milestone Pharmaceuticals Inc. is a private venture capital-funded cardiovascular drug development company developing novel small molecule therapeutics for transient cardiovascular conditions. The company’s lead product, etripamil (MSP-2017), is entering Phase 3 development. Etripamil is a potent and short-acting nasally-delivered calcium channel antagonist in development for the episodic treatment of paroxysmal supraventricular tachycardia (PSVT).
Milestone Pharmaceuticals Closes $55 Million Series C Financing
- Proceeds to Fund Etripamil Phase 3 Development and Pre-Launch Market Development -
Montreal, QC, CA, August 1, 2017 – Milestone Pharmaceuticals Montreal, Canada, Inc., a clinical stage cardiovascular company, today announced the completion of a US$55 million Series C financing.